Cargando…

Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays

The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein p...

Descripción completa

Detalles Bibliográficos
Autores principales: Esposito, Dominic, Mehalko, Jennifer, Drew, Matthew, Snead, Kelly, Wall, Vanessa, Taylor, Troy, Frank, Peter, Denson, John-Paul, Hong, Min, Gulten, Gulcin, Sadtler, Kaitlyn, Messing, Simon, Gillette, William
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265690/
https://www.ncbi.nlm.nih.gov/pubmed/32511418
http://dx.doi.org/10.1101/2020.05.27.120204
_version_ 1783541176928829440
author Esposito, Dominic
Mehalko, Jennifer
Drew, Matthew
Snead, Kelly
Wall, Vanessa
Taylor, Troy
Frank, Peter
Denson, John-Paul
Hong, Min
Gulten, Gulcin
Sadtler, Kaitlyn
Messing, Simon
Gillette, William
author_facet Esposito, Dominic
Mehalko, Jennifer
Drew, Matthew
Snead, Kelly
Wall, Vanessa
Taylor, Troy
Frank, Peter
Denson, John-Paul
Hong, Min
Gulten, Gulcin
Sadtler, Kaitlyn
Messing, Simon
Gillette, William
author_sort Esposito, Dominic
collection PubMed
description The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein produced from transient transfection of HEK293 cells will be a limiting factor for these assays. To improve the yield of spike protein and support the high demand for antigens in serology assays, we investigated several recombinant protein expression variables by altering the incubation temperature, harvest time, chromatography strategy, and final protein manipulation. Through this investigation, we developed a simplified and robust purification strategy that consistently yields 5 mg of protein per liter of expression culture for two commonly used forms of the SARS-CoV-2 spike protein. We show that these proteins form well-behaved stable trimers and are consistently functional in serology assays across multiple protein production lots.
format Online
Article
Text
id pubmed-7265690
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Cold Spring Harbor Laboratory
record_format MEDLINE/PubMed
spelling pubmed-72656902020-06-07 Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays Esposito, Dominic Mehalko, Jennifer Drew, Matthew Snead, Kelly Wall, Vanessa Taylor, Troy Frank, Peter Denson, John-Paul Hong, Min Gulten, Gulcin Sadtler, Kaitlyn Messing, Simon Gillette, William bioRxiv Article The SARS-CoV-2 spike trimer is the primary antigen for several serology assays critical to determining the extent of SARS-CoV-2 exposure in the population. Until stable cell lines are developed to increase the titer of this secreted protein in mammalian cell culture, the low yield of spike protein produced from transient transfection of HEK293 cells will be a limiting factor for these assays. To improve the yield of spike protein and support the high demand for antigens in serology assays, we investigated several recombinant protein expression variables by altering the incubation temperature, harvest time, chromatography strategy, and final protein manipulation. Through this investigation, we developed a simplified and robust purification strategy that consistently yields 5 mg of protein per liter of expression culture for two commonly used forms of the SARS-CoV-2 spike protein. We show that these proteins form well-behaved stable trimers and are consistently functional in serology assays across multiple protein production lots. Cold Spring Harbor Laboratory 2020-05-28 /pmc/articles/PMC7265690/ /pubmed/32511418 http://dx.doi.org/10.1101/2020.05.27.120204 Text en https://creativecommons.org/publicdomain/zero/1.0/This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license (https://creativecommons.org/publicdomain/zero/1.0/) .
spellingShingle Article
Esposito, Dominic
Mehalko, Jennifer
Drew, Matthew
Snead, Kelly
Wall, Vanessa
Taylor, Troy
Frank, Peter
Denson, John-Paul
Hong, Min
Gulten, Gulcin
Sadtler, Kaitlyn
Messing, Simon
Gillette, William
Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_full Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_fullStr Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_full_unstemmed Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_short Optimizing high-yield production of SARS-CoV-2 soluble spike trimers for serology assays
title_sort optimizing high-yield production of sars-cov-2 soluble spike trimers for serology assays
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7265690/
https://www.ncbi.nlm.nih.gov/pubmed/32511418
http://dx.doi.org/10.1101/2020.05.27.120204
work_keys_str_mv AT espositodominic optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT mehalkojennifer optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT drewmatthew optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT sneadkelly optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT wallvanessa optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT taylortroy optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT frankpeter optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT densonjohnpaul optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT hongmin optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT gultengulcin optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT sadtlerkaitlyn optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT messingsimon optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays
AT gillettewilliam optimizinghighyieldproductionofsarscov2solublespiketrimersforserologyassays